Investigational Drug Information for BLD-2660
✉ Email this page to a colleague
What is the development status for investigational drug BLD-2660?
BLD-2660 is an investigational drug.
There have been 4 clinical trials for BLD-2660.
The most recent clinical trial was a Phase 1 trial, which was initiated on December 15th 2019.
The most common disease conditions in clinical trials are Fibrosis, Idiopathic Pulmonary Fibrosis, and Liver Cirrhosis. The leading clinical trial sponsors are Blade Therapeutics, Clinipace Worldwide, and [disabled in preview].
Summary for BLD-2660
US Patents | 0 |
International Patents | 0 |
US Patent Applications | 5 |
WIPO Patent Applications | 1 |
Japanese Patent Applications | 1 |
Clinical Trial Progress | Phase 1 (2019-12-15) |
Vendors | 16 |
Recent Clinical Trials for BLD-2660
Title | Sponsor | Phase |
---|---|---|
Healthy Volunteer Study Comparing Tablet and Capsule Formulations | Blade Therapeutics | Phase 1 |
Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects | Clinipace Worldwide | Phase 2 |
Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects | Blade Therapeutics | Phase 2 |
Clinical Trial Summary for BLD-2660
Top disease conditions for BLD-2660
Top clinical trial sponsors for BLD-2660
US Patents for BLD-2660
Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
---|---|---|---|---|
>Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |